The PD-L1 Inhibitors drugs uptake section examines the rate at which newly launched or upcoming potential drugs are being ...

Imfinzi remains a key revenue driver for AstraZeneca’s oncology portfolio. In the first quarter of 2025, Imfinzi generated sales of $1.26 billion, up 16%, driven by demand growth in lung and ...

Imfinzi has been approved in the US and other countries for the same indication based on the NIAGARA results, with regulatory applications under review in Japan and several other countries.

With sales of its lone product in a precipitous decline in the United States, Amarin has turned to an experienced local ...

Imfinzi recommended in EU for bladder cancer | Regulatory News ...

IMFINZI® (durvalumab) regimen reduced risk of progression, recurrence or death by 29% in early-stage gastric cancer vs. chemotherapy alone in MATTERHORN Phase III trial Business Wire Jun 1, 2025 ...

Susan Galbraith, Executive Vice President, Oncology Haematology R&D, AstraZeneca, said, "The Imfinzi-based perioperative regimen in the NIAGARA Phase III trial enabled survival of more than 80 per ...

AstraZeneca’s Imfinzi (durvalumab) has been recommended for approval in the European Union (EU) for the treatment of adult patients with resectable muscle-invasive bladder cancer (MIBC) in combination ...

The ovarian cancer market has transformed in recent years, driven by the expanding use of PARP inhibitors, antiangiogenic ...

(Alliance News) - AstraZeneca PLC on Tuesday said its Imfinzi, or durvalumab, therapy has been recommended for approval in the EU for the treatment of muscle-invasive bladder cancer. The Cambridge ...